{"ticker": {"uuid": "76f3efd1-be0c-4593-9eb5-e5d69c4511cd", "symbol": "CLNN", "name": "Clene Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Consumer Defensive", "industry": "Packaged Foods"}, "articles": [{"title": "Enterprise value to EBIT forward of Clene Inc. \u2013 NASDAQ:CLNN", "summary": "This article provides financial data for Clene Inc. (NASDAQ:CLNN), specifically focusing on its enterprise value to EBIT forward. It appears to be a financial snapshot from TradingView, offering an overview of the company's financial metrics. The original content is primarily nav", "url": "https://www.tradingview.com/symbols/NASDAQ-CLNN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T00:11:22", "published_display": "15 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Clene Inc \u2013 FWB:84C0", "summary": "This article focuses on the enterprise value to revenue forward of Clene Inc (FWB:84C0) based in the Health Technology sector. It presents financial overview, news, documents, community forecasts, and seasonal data for the company on the Frankfurt Stock Exchange. The webpage is p", "url": "https://www.tradingview.com/symbols/FWB-84C0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T01:39:11", "published_display": "13 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Q2 Virtual Investor Summit Event earnings summary", "summary": "Clene (CLNN) held a Q2 Virtual Investor Summit focusing on its strategic commitment to neurodegenerative diseases, particularly ALS, MS, and Parkinson's, using its catalytic nanotherapeutic, Au8. The company reported on clinical trials for ALS and MS, noting that while primary en", "url": "https://quartr.com/events/clene-inc-clnn-q2-virtual-investor-summit-event_FPxtiAYS", "source_name": "Quartr", "published_at": "2026-07-10T16:40:40", "published_display": "10 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Clene Inc \u2013 FWB:84C0", "summary": "This page provides financial data for Clene Inc (FWB:84C0) on the Frankfurt Stock Exchange, specifically focusing on its Enterprise Value to EBIT forward. It indicates that the market is currently closed with no trades. The content primarily lists various general TradingView feat", "url": "https://www.tradingview.com/symbols/FWB-84C0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T23:10:49", "published_display": "09 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Study Update Summary", "summary": "Clene (CLNN) has provided an update on its study findings for CNM-Au8, focusing on its potential as a treatment for ALS. The FDA has indicated willingness to consider neurofilament light (NfL) as a surrogate endpoint for accelerated approval, provided biomarker changes predict cl", "url": "https://quartr.com/events/clene-inc-clnn-study-update_FPxti7uI", "source_name": "Quartr", "published_at": "2026-07-09T03:05:50", "published_display": "09 Jul 2026 03:05", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Proxy filing Summary", "summary": "Clene (CLNN) has released a proxy filing summary detailing the agenda for its annual meeting on May 21, 2026. Shareholders will vote on the election of three Class III directors, ratification of Deloitte & Touche LLP as the independent accounting firm, advisory approval of compen", "url": "https://quartr.com/events/clene-inc-clnn-proxy-filing_FPxtQBUl", "source_name": "Quartr", "published_at": "2026-07-09T02:39:11", "published_display": "09 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Registration Filing Summary", "summary": "This article summarizes Clene's (CLNN) registration filing, outlining its business model as a clinical-stage pharmaceutical company developing nanotechnology therapeutics for CNS disorders. It details the company's financial performance, including significant operating losses and", "url": "https://quartr.com/events/clene-inc-clnn-registration-filing_FPxti2Vx", "source_name": "Quartr", "published_at": "2026-07-08T15:11:22", "published_display": "08 Jul 2026 15:11", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Emerging Growth Conference 92 Summary", "summary": "Clene (CLNN) presented a summary of its Emerging Growth Conference 92, detailing regulatory progress for its ALS treatment. The company received positive FDA post-meeting minutes, indicating data may support an NDA submission, with neurofilament light reduction being pursued as a", "url": "https://quartr.com/events/clene-inc-clnn-emerging-growth-conference-92_FPxtQmUN", "source_name": "Quartr", "published_at": "2026-07-08T13:41:07", "published_display": "08 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Q4 2025 earnings summary", "summary": "Clene (CLNN) held an in-person FDA Type C meeting for CNM-Au8 data by the end of Q1 2026, with plans to file an NDA for CNM-Au8 in ALS under accelerated approval by the end of June 2026. The company also completed an oversubscribed $28M direct offering, extending its cash runway.", "url": "https://quartr.com/events/clene-inc-clnn-q4-2025_FPxtim10", "source_name": "Quartr", "published_at": "2026-07-08T13:41:07", "published_display": "08 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Q1 2026 earnings summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE5VSktsMW1lcFhnUXJ0cGM2dmpvS1lTekNIQ1QwNU5TSTBBams2WmxpcnNiVGZ6RkhuaFRfMlJ2czdRbXRrZnR3cEl4c3U1SGtUbFY0UGRZOC1ELUFpQ1BsUkhzWmJyVmNP?oc=5", "source_name": "Quartr", "published_at": "2026-07-08T01:31:43+00:00", "published_display": "08 Jul 2026 01:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Emerging Growth Virtual Conference Summary", "summary": "Clene (CLNN) presented a summary of its Emerging Growth Virtual Conference, highlighting its focus on therapies for neurodegenerative diseases like ALS and MS, with lead asset CNM-Au8. The company reported statistically significant reductions in biomarkers and survival benefits i", "url": "https://quartr.com/events/clene-inc-clnn-emerging-growth-virtual-conference_FPxtQ6eF", "source_name": "Quartr", "published_at": "2026-07-08T02:11:18", "published_display": "08 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Clene Inc. \u2013 NASDAQ:CLNN", "summary": "The article focuses on the enterprise value to EBITDA forward metric for Clene Inc. (NASDAQ: CLNN). It presents this financial data point within the context of TradingView's platform, indicating its relevance for investors and financial analysts. The article itself is very brief,", "url": "https://www.tradingview.com/symbols/NASDAQ-CLNN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:56", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc Actuals & Estimates (NASDAQ:CLNN)", "summary": "This article provides an overview of Clene Inc. (NASDAQ: CLNN) stock, including its current price, performance trends, analyst forecasts, and financial data. It covers historical price movements, market capitalization, volatility, and upcoming earnings reports, along with past ea", "url": "https://www.tradingview.com/symbols/NASDAQ-CLNN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:53", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Clene Inc. \u2013 BOATS:CLNN", "summary": "This article provides financial information for Clene Inc. (CLNN) on the Blue Ocean Alternative Trade System (BOATS). It specifically focuses on the company's \"Price to earnings forward\" metric. The content highlights the period, value, and change information for this financial i", "url": "https://www.tradingview.com/symbols/BOATS-CLNN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:42:15", "published_display": "26 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Clene Inc. \u2013 BOATS:CLNN", "summary": "This article provides the enterprise value to EBIT forward for Clene Inc. (CLNN) as traded on the Blue Ocean Alternative Trade System (BOATS). It presents financial data with disclaimers regarding its sourcing from ICE Data Services and FactSet Research Systems Inc., and intellec", "url": "https://www.tradingview.com/symbols/BOATS-CLNN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:28", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLNN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Clene Inc. (CLNN) stock for 2027, based on analyst opinions. It includes current stock performance metrics, historical high and low prices, market capitalization, volatility, and details on past and upcoming earnings and revenu", "url": "https://www.tradingview.com/symbols/NASDAQ-CLNN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-24T13:11:18", "published_display": "24 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Clene Inc. (CLNN) has a weak financial status with a current score of 5.65, ranking low in the Biotechnology & Medical Research industry. The company reported a significant year-over-year decrease in revenue by 81.48% and a net profit decrease of 977.36% in its latest quarterly r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T19:10:36", "published_display": "23 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNNW) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Clene Inc. (CLNNW), focusing on indicators and moving averages. It details the current status of various technical indicators like MACD, RSI, and STOCH, along with an overview of moving averages from MA5 to MA200. The analysis indicat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnnw/technical", "source_name": "TradingKey", "published_at": "2026-06-19T07:49:04", "published_display": "19 Jun 2026 07:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNNW) Institutional Confidence", "summary": "This article provides an overview of Clene Inc.'s (CLNNW) institutional confidence, focusing on shareholder activity. It shows changes in shares held by various institutional investors, with several firms significantly reducing or eliminating their holdings. The report highlights", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnnw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T00:49:03", "published_display": "19 Jun 2026 00:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Clene Inc. (CLNN) currently has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have set an average price target of $30.00 for CLNN, with an expected revenue of $73.50K for the next quarter. Most analysts recommend a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnn/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T12:40:12", "published_display": "18 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNNW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Clene Inc. (CLNNW) focusing on its dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years and has no recorded stock split data. The page also presents basic stock information", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnnw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T08:40:12", "published_display": "18 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article for Clene Inc. (CLNN) on TradingKey discusses the company's revenue breakdown, including business segments and regional contributions. However, it notes that relevant data for these categories have not been disclosed by the company yet. The article provides current s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:28", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Clene Inc.'s (CLNN) dividend history and stock split events. It states that Clene Inc. has distributed no dividends over the past five years. The article also lists upcoming stock split events, all identified as \"Merger 20\u21921\" on July 9, 2024.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:28", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) CEO receives 65,000 stock options at $5.53 exercise price", "summary": "Clene Inc. President and CEO Robert Dee Etherington was granted 65,000 stock options with an exercise price of $5.53 per share, expiring on June 10, 2036. The options will vest 25% on June 11, 2027, with the remainder vesting in 36 equal monthly installments thereafter. This gran", "url": "https://www.stocktitan.net/sec-filings/CLNN/form-4-clene-inc-insider-trading-activity-fbdf33a448fd.html", "source_name": "Stock Titan", "published_at": "2026-06-15T18:39:45", "published_display": "15 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Chief Science Officer receives 45,000-share stock option grant", "summary": "Clene Inc.'s Chief Science Officer, Mark Mortenson, was granted stock options for 45,000 shares with an exercise price of $5.53 per share, expiring in 2036. This compensation-related award vests 25% on June 11, 2027, with the remainder vesting in 36 equal monthly installments the", "url": "https://www.stocktitan.net/sec-filings/CLNN/form-4-clene-inc-insider-trading-activity-4ea576ad0d8c.html", "source_name": "Stock Titan", "published_at": "2026-06-15T18:39:45", "published_display": "15 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) grants CFO 15,000 stock options at $5.53 strike", "summary": "Clene Inc. (CLNN) has granted its Chief Financial Officer, Morgan R. Brown, 15,000 stock options with an exercise price of $5.53 per share, expiring on June 10, 2036. The options will vest 25% on June 11, 2027, with the remaining 75% vesting in 36 equal monthly installments there", "url": "https://www.stocktitan.net/sec-filings/CLNN/form-4-clene-inc-insider-trading-activity-9aa5cb23066b.html", "source_name": "Stock Titan", "published_at": "2026-06-15T18:39:45", "published_display": "15 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPMFR5MXROXzRDSHNZSkxfRXhCNlF0MjQzdzRXWUVUWDhlR1BvOE1mdzctYkxuY0hxZEdYaGJrd28tQWk5VlZWNmtEemR0QXNGU3dWY0gxdlFOaEVYSVppcU14TzZYNFVkSTFxbUl5UHl3eWhuUUw5Rl9RZTVKSkIzRmlwQ25pelZwZHVtNkpzZG9XdlFUNXc?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLNN Technical Analysis & Stock Price Forecast", "summary": "The article provides a technical analysis and stock price forecast for Clene Inc (CLNN), indicating a Neutral overall consensus based on various technical indicators as of May 29, 2026. It details momentum indicators like RSI and MACD, support and resistance levels, and different", "url": "https://intellectia.ai/en/stock/CLNN/technical", "source_name": "Intellectia AI", "published_at": "2026-05-30T05:09:57", "published_display": "30 May 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Moves Toward Accelerated Approval NDA Filing for CNM-Au8 in ALS", "summary": "Clene Nanoscience plans to submit an NDA for accelerated FDA approval of its investigational agent CNM-Au8 for ALS treatment, primarily based on neurofilament light (NfL) biomarker data and phase 2 studies. The FDA indicated that the available dataset might support review under a", "url": "https://www.neurologylive.com/view/clene-moves-toward-accelerated-approval-nda-filing-cnm-au8-als", "source_name": "NeurologyLive", "published_at": "2026-05-23T18:41:22", "published_display": "23 May 2026 18:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLNN stock rises 8% \u2013 here\u2019s what the FDA update means for Clene\u2019s ALS treatment", "summary": "CLNN stock saw an 8% increase today following an FDA update regarding Clene's investigational ALS treatment, CNM-Au8. The FDA granted a Fast Track designation for the drug, indicating it addresses an unmet medical need for a serious condition. This designation will expedite the r", "url": "https://www.msn.com/ar-eg/health/other/clnn-stock-rises-8-here-s-what-the-fda-update-means-for-clene-s-als-treatment/ar-AA22mVYG", "source_name": "MSN", "published_at": "2026-05-23T15:38:45", "published_display": "23 May 2026 15:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNQm1XUllhb1JYN0lZSnhLVW80N1lXd0VkalFtNVpQeWg1clk0Ny1NeDBxR21WcGJXREFKQmYzQUpZQWZhX1FPUk1XcTAwTVVpVnZUTWFtU2dyUXZsVWd4cllZNEpaYUhRcE5iN2E3ak1rM0xMZ1BaYTNRQ3QyeTRSVnhUdzAtTzhKSnYyUVRJbDVPb3pD?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Major Clene (CLNN) holder SymBiosis II, LLC sells 95,473 shares, keeps stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQSkI5T2RCTDBRbjUyNS1fSEoycGQxbUcxNTFtT1YwV2hQT2VvaG9vMXhHajlzYmoyTmFhc2hValhaWGlnNzNNbTlTdUsyYUNURFNLYVA0MzYwMUl3S3U4NU5MZE95YmtiWmZZa1dvdVNqbnlkd0pmTWQwUlZQMzM2U2tXeFFiNHhTbVFOa1FoUHphbjhvM1BwRzJIUk5XLWxpUWtyakF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. Announces Pricing of $7 Million Registered Direct Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNXzU2enJzOU1IVW9tbWlVelBMNTd6MXExRU9xVnRHSS1EQWN3dE53akNDM2tPZWVDNGw1cWV0bXpKb2ZjenA0QUk1LXpaeXVtUktkTEN6ZlI5SHh5SHJYaVpiRC15R2UtV1MzMmFBTU1WaWkxZF84WVR5Z2dtanREY0draFozdW9iMTNEVzA5alp0Q2lvbG95Q0g5TkdwVmR6b1RxVGdCQTZPcFRMZUhzWFY0N2xWSWE4MlFyZQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene sells 1M shares to fund ALS drug filing and Phase 3 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOcnBFbkVTLUZWa21vY2Nrel8xRmQyeGZvVVA1Qll2UjV3QWRIYW84akRqa2NOOVNxb0J1UHRHRVJLUmxVQ1FDZzRFVngwcHdKTk9sWFFQZENZUWdaSF9NQV9VUXRob2FWZzZ6aV9Zai1yc01xWnJ3WjR6YWdEN21XYi16RklhY3FrcVN1TzdtbVdzRFdxei1iOG9saWlUNEZOd0p2bkFJRUFNX1RFR0QzVXl3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene stock tumbles after pricing $7M stock offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNNlgwUVR2blJaeUxteGFPUlhLa3lrSWI0allvOGRkZ0N3TVVRdGhQSnoxdlFhc0xlRDlSSGtUcHJxT0VJYV9qTVhMMGxHMjFFdnM1S3dxTUh3RmhEYUZycUdEWERhNXF3cGtIMW1lZVhmbVpWQ1BXNHlieVlMTTBhUC1UT2Q0NzhrVHB6NU1fLW50enZvVnRIbldRUm9abkpuSkFoazdWUGZlTkVtWW1SWjVySQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene lines up May 6 webcast and New York investor meetings May 7", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPUk9fUFAxTkhhNHVpUzJxTlZ6RFhHWHpKU1FCa0NPYThpVFdmX0FWdTNOQzJ3czhqWmZuUXJnd3hza0VQMUVyaGxLLUF5b1JwbVhXRFdjQWpkSGJVdU43XzNMcUhSX2U4VTVPbWdLd09rc3d3eW9wZ21MTTdYNUl6Vkx6SjlDQUF3NGNfM0xicG8?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene plans ALS drug filing after FDA says data may support faster review", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQdmlaMFpSSTAtb1p0V2FpY203dEZBR3p6VVFiOHJXMUd4dG1kQzUtcVM4OFpsNm0ycUN5U1VpX3ZDQ2xKazFLT1I4REhMSHJiSmxtNmZ4SEVPZ19GanJidldmLV95ZHROckx6b2VUQnVNQlB5VE41UkpaSU5xdFRLT0FROXlQNzVLUVE3UU03SUZ5Mmthdm40U0tmSndva1Y2d3EweGRiWHFyVmlWOGFLMFhGQS04UkNxYncxLUpR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (NASDAQ: CLNN) 10% holder SymBiosis II sells 65,663 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPY3MwR1hkTk5VejVkcFQ1ZHU3LWlobjA5QnAydEFnWG44RFkxR1lfV0tnajZpc1MzSzFfSFNVVGFoeVlPVi1ETUUydUphVUxsbV94X1dSc0gwVHIxbDZsMXFwdnRHc3djcnM3WTlVY2IzZGQxNnZrUi1PU2ZSTnFLUzRxWlEza05wM0ZmcEZrVGJQbUtCYXpPY0VzWUtLOV83a3AtVHVB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will Clene Inc. (NASDAQ:CLNN) Turn A Profit?", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9BOFZuMTJJYkZ5d2p1UTFpb2QtcTVhVEVzLWdqSnYwZEk1RW1LcWNCTzNuRGtpUmx3UU5qRFVCcF9JRk1VUEU2bmZWcU5aV1RUT3FHeGp5b1pfN0FjZnlnaTFyRXgwQlpoRnBPdVMtUjlIYkp5OFR3RER6QU4?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBTa19fUy1JY0FvSWdKTmlLX1YwQjFLTnhLWnhWRXVqeEJLUHFnbkZYU2VVVk9NbUdEWFZMQXh4MDN6Z0RIMHFLblpPa0xId2VsUk1VNnJHZGFLUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-01-06T13:40:21+00:00", "published_display": "06 Jan 2021 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBIT forward of Clene Inc. \u2013 NASDAQ:CLNN", "summary": "This article provides financial data for Clene Inc. (NASDAQ:CLNN), specifically focusing on its enterprise value to EBIT forward. It appears to be a financial snapshot from TradingView, offering an overview of the company's financial metrics. The original content is primarily nav", "url": "https://www.tradingview.com/symbols/NASDAQ-CLNN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T00:11:22", "published_display": "15 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Clene Inc \u2013 FWB:84C0", "summary": "This article focuses on the enterprise value to revenue forward of Clene Inc (FWB:84C0) based in the Health Technology sector. It presents financial overview, news, documents, community forecasts, and seasonal data for the company on the Frankfurt Stock Exchange. The webpage is p", "url": "https://www.tradingview.com/symbols/FWB-84C0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T01:39:11", "published_display": "13 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Q2 Virtual Investor Summit Event earnings summary", "summary": "Clene (CLNN) held a Q2 Virtual Investor Summit focusing on its strategic commitment to neurodegenerative diseases, particularly ALS, MS, and Parkinson's, using its catalytic nanotherapeutic, Au8. The company reported on clinical trials for ALS and MS, noting that while primary en", "url": "https://quartr.com/events/clene-inc-clnn-q2-virtual-investor-summit-event_FPxtiAYS", "source_name": "Quartr", "published_at": "2026-07-10T16:40:40", "published_display": "10 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Clene Inc \u2013 FWB:84C0", "summary": "This page provides financial data for Clene Inc (FWB:84C0) on the Frankfurt Stock Exchange, specifically focusing on its Enterprise Value to EBIT forward. It indicates that the market is currently closed with no trades. The content primarily lists various general TradingView feat", "url": "https://www.tradingview.com/symbols/FWB-84C0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T23:10:49", "published_display": "09 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Study Update Summary", "summary": "Clene (CLNN) has provided an update on its study findings for CNM-Au8, focusing on its potential as a treatment for ALS. The FDA has indicated willingness to consider neurofilament light (NfL) as a surrogate endpoint for accelerated approval, provided biomarker changes predict cl", "url": "https://quartr.com/events/clene-inc-clnn-study-update_FPxti7uI", "source_name": "Quartr", "published_at": "2026-07-09T03:05:50", "published_display": "09 Jul 2026 03:05", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Proxy filing Summary", "summary": "Clene (CLNN) has released a proxy filing summary detailing the agenda for its annual meeting on May 21, 2026. Shareholders will vote on the election of three Class III directors, ratification of Deloitte & Touche LLP as the independent accounting firm, advisory approval of compen", "url": "https://quartr.com/events/clene-inc-clnn-proxy-filing_FPxtQBUl", "source_name": "Quartr", "published_at": "2026-07-09T02:39:11", "published_display": "09 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Registration Filing Summary", "summary": "This article summarizes Clene's (CLNN) registration filing, outlining its business model as a clinical-stage pharmaceutical company developing nanotechnology therapeutics for CNS disorders. It details the company's financial performance, including significant operating losses and", "url": "https://quartr.com/events/clene-inc-clnn-registration-filing_FPxti2Vx", "source_name": "Quartr", "published_at": "2026-07-08T15:11:22", "published_display": "08 Jul 2026 15:11", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Emerging Growth Conference 92 Summary", "summary": "Clene (CLNN) presented a summary of its Emerging Growth Conference 92, detailing regulatory progress for its ALS treatment. The company received positive FDA post-meeting minutes, indicating data may support an NDA submission, with neurofilament light reduction being pursued as a", "url": "https://quartr.com/events/clene-inc-clnn-emerging-growth-conference-92_FPxtQmUN", "source_name": "Quartr", "published_at": "2026-07-08T13:41:07", "published_display": "08 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Q4 2025 earnings summary", "summary": "Clene (CLNN) held an in-person FDA Type C meeting for CNM-Au8 data by the end of Q1 2026, with plans to file an NDA for CNM-Au8 in ALS under accelerated approval by the end of June 2026. The company also completed an oversubscribed $28M direct offering, extending its cash runway.", "url": "https://quartr.com/events/clene-inc-clnn-q4-2025_FPxtim10", "source_name": "Quartr", "published_at": "2026-07-08T13:41:07", "published_display": "08 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Q1 2026 earnings summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE5VSktsMW1lcFhnUXJ0cGM2dmpvS1lTekNIQ1QwNU5TSTBBams2WmxpcnNiVGZ6RkhuaFRfMlJ2czdRbXRrZnR3cEl4c3U1SGtUbFY0UGRZOC1ELUFpQ1BsUkhzWmJyVmNP?oc=5", "source_name": "Quartr", "published_at": "2026-07-08T01:31:43+00:00", "published_display": "08 Jul 2026 01:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Emerging Growth Virtual Conference Summary", "summary": "Clene (CLNN) presented a summary of its Emerging Growth Virtual Conference, highlighting its focus on therapies for neurodegenerative diseases like ALS and MS, with lead asset CNM-Au8. The company reported statistically significant reductions in biomarkers and survival benefits i", "url": "https://quartr.com/events/clene-inc-clnn-emerging-growth-virtual-conference_FPxtQ6eF", "source_name": "Quartr", "published_at": "2026-07-08T02:11:18", "published_display": "08 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Clene Inc. \u2013 NASDAQ:CLNN", "summary": "The article focuses on the enterprise value to EBITDA forward metric for Clene Inc. (NASDAQ: CLNN). It presents this financial data point within the context of TradingView's platform, indicating its relevance for investors and financial analysts. The article itself is very brief,", "url": "https://www.tradingview.com/symbols/NASDAQ-CLNN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:56", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc Actuals & Estimates (NASDAQ:CLNN)", "summary": "This article provides an overview of Clene Inc. (NASDAQ: CLNN) stock, including its current price, performance trends, analyst forecasts, and financial data. It covers historical price movements, market capitalization, volatility, and upcoming earnings reports, along with past ea", "url": "https://www.tradingview.com/symbols/NASDAQ-CLNN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:53", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Clene Inc. \u2013 BOATS:CLNN", "summary": "This article provides financial information for Clene Inc. (CLNN) on the Blue Ocean Alternative Trade System (BOATS). It specifically focuses on the company's \"Price to earnings forward\" metric. The content highlights the period, value, and change information for this financial i", "url": "https://www.tradingview.com/symbols/BOATS-CLNN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:42:15", "published_display": "26 Jun 2026 00:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Clene Inc. \u2013 BOATS:CLNN", "summary": "This article provides the enterprise value to EBIT forward for Clene Inc. (CLNN) as traded on the Blue Ocean Alternative Trade System (BOATS). It presents financial data with disclaimers regarding its sourcing from ICE Data Services and FactSet Research Systems Inc., and intellec", "url": "https://www.tradingview.com/symbols/BOATS-CLNN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:28", "published_display": "25 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLNN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Clene Inc. (CLNN) stock for 2027, based on analyst opinions. It includes current stock performance metrics, historical high and low prices, market capitalization, volatility, and details on past and upcoming earnings and revenu", "url": "https://www.tradingview.com/symbols/NASDAQ-CLNN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-24T13:11:18", "published_display": "24 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Clene Inc. (CLNN) has a weak financial status with a current score of 5.65, ranking low in the Biotechnology & Medical Research industry. The company reported a significant year-over-year decrease in revenue by 81.48% and a net profit decrease of 977.36% in its latest quarterly r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T19:10:36", "published_display": "23 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNNW) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Clene Inc. (CLNNW), focusing on indicators and moving averages. It details the current status of various technical indicators like MACD, RSI, and STOCH, along with an overview of moving averages from MA5 to MA200. The analysis indicat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnnw/technical", "source_name": "TradingKey", "published_at": "2026-06-19T07:49:04", "published_display": "19 Jun 2026 07:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNNW) Institutional Confidence", "summary": "This article provides an overview of Clene Inc.'s (CLNNW) institutional confidence, focusing on shareholder activity. It shows changes in shares held by various institutional investors, with several firms significantly reducing or eliminating their holdings. The report highlights", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnnw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T00:49:03", "published_display": "19 Jun 2026 00:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Clene Inc. (CLNN) currently has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have set an average price target of $30.00 for CLNN, with an expected revenue of $73.50K for the next quarter. Most analysts recommend a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnn/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T12:40:12", "published_display": "18 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNNW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Clene Inc. (CLNNW) focusing on its dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years and has no recorded stock split data. The page also presents basic stock information", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnnw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T08:40:12", "published_display": "18 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article for Clene Inc. (CLNN) on TradingKey discusses the company's revenue breakdown, including business segments and regional contributions. However, it notes that relevant data for these categories have not been disclosed by the company yet. The article provides current s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:28", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Clene Inc.'s (CLNN) dividend history and stock split events. It states that Clene Inc. has distributed no dividends over the past five years. The article also lists upcoming stock split events, all identified as \"Merger 20\u21921\" on July 9, 2024.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-clnn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T17:39:28", "published_display": "17 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) CEO receives 65,000 stock options at $5.53 exercise price", "summary": "Clene Inc. President and CEO Robert Dee Etherington was granted 65,000 stock options with an exercise price of $5.53 per share, expiring on June 10, 2036. The options will vest 25% on June 11, 2027, with the remainder vesting in 36 equal monthly installments thereafter. This gran", "url": "https://www.stocktitan.net/sec-filings/CLNN/form-4-clene-inc-insider-trading-activity-fbdf33a448fd.html", "source_name": "Stock Titan", "published_at": "2026-06-15T18:39:45", "published_display": "15 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Chief Science Officer receives 45,000-share stock option grant", "summary": "Clene Inc.'s Chief Science Officer, Mark Mortenson, was granted stock options for 45,000 shares with an exercise price of $5.53 per share, expiring in 2036. This compensation-related award vests 25% on June 11, 2027, with the remainder vesting in 36 equal monthly installments the", "url": "https://www.stocktitan.net/sec-filings/CLNN/form-4-clene-inc-insider-trading-activity-4ea576ad0d8c.html", "source_name": "Stock Titan", "published_at": "2026-06-15T18:39:45", "published_display": "15 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) grants CFO 15,000 stock options at $5.53 strike", "summary": "Clene Inc. (CLNN) has granted its Chief Financial Officer, Morgan R. Brown, 15,000 stock options with an exercise price of $5.53 per share, expiring on June 10, 2036. The options will vest 25% on June 11, 2027, with the remaining 75% vesting in 36 equal monthly installments there", "url": "https://www.stocktitan.net/sec-filings/CLNN/form-4-clene-inc-insider-trading-activity-9aa5cb23066b.html", "source_name": "Stock Titan", "published_at": "2026-06-15T18:39:45", "published_display": "15 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPMFR5MXROXzRDSHNZSkxfRXhCNlF0MjQzdzRXWUVUWDhlR1BvOE1mdzctYkxuY0hxZEdYaGJrd28tQWk5VlZWNmtEemR0QXNGU3dWY0gxdlFOaEVYSVppcU14TzZYNFVkSTFxbUl5UHl3eWhuUUw5Rl9RZTVKSkIzRmlwQ25pelZwZHVtNkpzZG9XdlFUNXc?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLNN Technical Analysis & Stock Price Forecast", "summary": "The article provides a technical analysis and stock price forecast for Clene Inc (CLNN), indicating a Neutral overall consensus based on various technical indicators as of May 29, 2026. It details momentum indicators like RSI and MACD, support and resistance levels, and different", "url": "https://intellectia.ai/en/stock/CLNN/technical", "source_name": "Intellectia AI", "published_at": "2026-05-30T05:09:57", "published_display": "30 May 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Moves Toward Accelerated Approval NDA Filing for CNM-Au8 in ALS", "summary": "Clene Nanoscience plans to submit an NDA for accelerated FDA approval of its investigational agent CNM-Au8 for ALS treatment, primarily based on neurofilament light (NfL) biomarker data and phase 2 studies. The FDA indicated that the available dataset might support review under a", "url": "https://www.neurologylive.com/view/clene-moves-toward-accelerated-approval-nda-filing-cnm-au8-als", "source_name": "NeurologyLive", "published_at": "2026-05-23T18:41:22", "published_display": "23 May 2026 18:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLNN stock rises 8% \u2013 here\u2019s what the FDA update means for Clene\u2019s ALS treatment", "summary": "CLNN stock saw an 8% increase today following an FDA update regarding Clene's investigational ALS treatment, CNM-Au8. The FDA granted a Fast Track designation for the drug, indicating it addresses an unmet medical need for a serious condition. This designation will expedite the r", "url": "https://www.msn.com/ar-eg/health/other/clnn-stock-rises-8-here-s-what-the-fda-update-means-for-clene-s-als-treatment/ar-AA22mVYG", "source_name": "MSN", "published_at": "2026-05-23T15:38:45", "published_display": "23 May 2026 15:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNQm1XUllhb1JYN0lZSnhLVW80N1lXd0VkalFtNVpQeWg1clk0Ny1NeDBxR21WcGJXREFKQmYzQUpZQWZhX1FPUk1XcTAwTVVpVnZUTWFtU2dyUXZsVWd4cllZNEpaYUhRcE5iN2E3ak1rM0xMZ1BaYTNRQ3QyeTRSVnhUdzAtTzhKSnYyUVRJbDVPb3pD?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Major Clene (CLNN) holder SymBiosis II, LLC sells 95,473 shares, keeps stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQSkI5T2RCTDBRbjUyNS1fSEoycGQxbUcxNTFtT1YwV2hQT2VvaG9vMXhHajlzYmoyTmFhc2hValhaWGlnNzNNbTlTdUsyYUNURFNLYVA0MzYwMUl3S3U4NU5MZE95YmtiWmZZa1dvdVNqbnlkd0pmTWQwUlZQMzM2U2tXeFFiNHhTbVFOa1FoUHphbjhvM1BwRzJIUk5XLWxpUWtyakF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene Inc. Announces Pricing of $7 Million Registered Direct Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNXzU2enJzOU1IVW9tbWlVelBMNTd6MXExRU9xVnRHSS1EQWN3dE53akNDM2tPZWVDNGw1cWV0bXpKb2ZjenA0QUk1LXpaeXVtUktkTEN6ZlI5SHh5SHJYaVpiRC15R2UtV1MzMmFBTU1WaWkxZF84WVR5Z2dtanREY0draFozdW9iMTNEVzA5alp0Q2lvbG95Q0g5TkdwVmR6b1RxVGdCQTZPcFRMZUhzWFY0N2xWSWE4MlFyZQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene sells 1M shares to fund ALS drug filing and Phase 3 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOcnBFbkVTLUZWa21vY2Nrel8xRmQyeGZvVVA1Qll2UjV3QWRIYW84akRqa2NOOVNxb0J1UHRHRVJLUmxVQ1FDZzRFVngwcHdKTk9sWFFQZENZUWdaSF9NQV9VUXRob2FWZzZ6aV9Zai1yc01xWnJ3WjR6YWdEN21XYi16RklhY3FrcVN1TzdtbVdzRFdxei1iOG9saWlUNEZOd0p2bkFJRUFNX1RFR0QzVXl3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene stock tumbles after pricing $7M stock offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNNlgwUVR2blJaeUxteGFPUlhLa3lrSWI0allvOGRkZ0N3TVVRdGhQSnoxdlFhc0xlRDlSSGtUcHJxT0VJYV9qTVhMMGxHMjFFdnM1S3dxTUh3RmhEYUZycUdEWERhNXF3cGtIMW1lZVhmbVpWQ1BXNHlieVlMTTBhUC1UT2Q0NzhrVHB6NU1fLW50enZvVnRIbldRUm9abkpuSkFoazdWUGZlTkVtWW1SWjVySQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene lines up May 6 webcast and New York investor meetings May 7", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPUk9fUFAxTkhhNHVpUzJxTlZ6RFhHWHpKU1FCa0NPYThpVFdmX0FWdTNOQzJ3czhqWmZuUXJnd3hza0VQMUVyaGxLLUF5b1JwbVhXRFdjQWpkSGJVdU43XzNMcUhSX2U4VTVPbWdLd09rc3d3eW9wZ21MTTdYNUl6Vkx6SjlDQUF3NGNfM0xicG8?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene plans ALS drug filing after FDA says data may support faster review", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQdmlaMFpSSTAtb1p0V2FpY203dEZBR3p6VVFiOHJXMUd4dG1kQzUtcVM4OFpsNm0ycUN5U1VpX3ZDQ2xKazFLT1I4REhMSHJiSmxtNmZ4SEVPZ19GanJidldmLV95ZHROckx6b2VUQnVNQlB5VE41UkpaSU5xdFRLT0FROXlQNzVLUVE3UU03SUZ5Mmthdm40U0tmSndva1Y2d3EweGRiWHFyVmlWOGFLMFhGQS04UkNxYncxLUpR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (NASDAQ: CLNN) 10% holder SymBiosis II sells 65,663 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPY3MwR1hkTk5VejVkcFQ1ZHU3LWlobjA5QnAydEFnWG44RFkxR1lfV0tnajZpc1MzSzFfSFNVVGFoeVlPVi1ETUUydUphVUxsbV94X1dSc0gwVHIxbDZsMXFwdnRHc3djcnM3WTlVY2IzZGQxNnZrUi1PU2ZSTnFLUzRxWlEza05wM0ZmcEZrVGJQbUtCYXpPY0VzWUtLOV83a3AtVHVB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "When Will Clene Inc. (NASDAQ:CLNN) Turn A Profit?", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9BOFZuMTJJYkZ5d2p1UTFpb2QtcTVhVEVzLWdqSnYwZEk1RW1LcWNCTzNuRGtpUmx3UU5qRFVCcF9JRk1VUEU2bmZWcU5aV1RUT3FHeGp5b1pfN0FjZnlnaTFyRXgwQlpoRnBPdVMtUjlIYkp5OFR3RER6QU4?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clene (CLNN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBTa19fUy1JY0FvSWdKTmlLX1YwQjFLTnhLWnhWRXVqeEJLUHFnbkZYU2VVVk9NbUdEWFZMQXh4MDN6Z0RIMHFLblpPa0xId2VsUk1VNnJHZGFLUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-01-06T13:40:21+00:00", "published_display": "06 Jan 2021 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 90, "total_relevant": 40, "sentiment_summary": {"positive": 10, "negative": 3, "neutral": 27, "score": 53, "total": 40, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 10.45, "count": 19}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.75, "count": 5}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 6.27, "latest_week": "2026-07-10", "one_week_move": 2.8, "four_week_move": 7.4, "twelve_week_move": -0.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.029624, "market_dynamics_buy_signal": false, "relative_strength": -13.631441, "fair_value_gap": -5.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 41.8451, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.8% over one week, +7.4% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Quartr", "count": 8}, {"label": "Stock Titan", "count": 8}, {"label": "TradingKey", "count": 7}, {"label": "Market source", "count": 3}, {"label": "Intellectia AI", "count": 1}, {"label": "NeurologyLive", "count": 1}, {"label": "MSN", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 19}, {"label": "Earnings", "count": 11}, {"label": "Regulatory and legal", "count": 5}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.8% over one week, +7.4% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBIT forward of Clene Inc. \u2013 NASDAQ:CLNN"}], "updated_at": "2026-07-16T04:34:43.349635+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}